{
    "id": 25300,
    "fullName": "CTNNB1 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "CTNNB1 over exp indicates an over expression of the Ctnnb1 protein and/or mRNA. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 1499,
        "geneSymbol": "CTNNB1",
        "terms": [
            "CTNNB1",
            "armadillo",
            "CTNNB",
            "EVR7",
            "MRD19",
            "NEDSDV"
        ]
    },
    "variant": "over exp",
    "createDate": "08/31/2016",
    "updateDate": "08/24/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 10333,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of NVP-TNKS656 and Triciribine (API-2) inhibited tumor growth in Triciribine (API-2)-resistant patient-derived xenograft (PDX) models of colon cancer with high nuclear CTNNB1 (Beta-catenin) levels (PMID: 26224873).",
            "molecularProfile": {
                "id": 26160,
                "profileName": "CTNNB1 over exp"
            },
            "therapy": {
                "id": 5469,
                "therapyName": "NVP-TNKS656 + Triciribine",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8313,
                    "pubMedId": 26224873,
                    "title": "Tankyrase Inhibition Blocks Wnt/\u03b2-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26224873"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8118,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Odomzo (sonidegib) inhibited survival of tumor cells derived from spontaneous medulloblastoma of heterozygous PTCH1 knockout mice over expressing wild-type Ctnnb1 in culture (PMID: 26130651).",
            "molecularProfile": {
                "id": 26161,
                "profileName": "CTNNB1 over exp PTCH1 inact mut"
            },
            "therapy": {
                "id": 1428,
                "therapyName": "Sonidegib",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6547,
                    "pubMedId": 26130651,
                    "title": "RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26130651"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10331,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NVP-TNKS656 inhibited tumor growth in a patient-derived xenograft model of metastatic colon cancer expressing high levels of nuclear CTNNB1 (Beta-catenin) and FOXO3 (PMID: 26224873).",
            "molecularProfile": {
                "id": 27360,
                "profileName": "CTNNB1 over exp FOXO3 over exp"
            },
            "therapy": {
                "id": 5467,
                "therapyName": "NVP-TNKS656",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8313,
                    "pubMedId": 26224873,
                    "title": "Tankyrase Inhibition Blocks Wnt/\u03b2-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26224873"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26160,
            "profileName": "CTNNB1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26161,
            "profileName": "CTNNB1 over exp PTCH1 inact mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27360,
            "profileName": "CTNNB1 over exp FOXO3 over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}